Journal: Journal of tissue engineering

Article Title: Extracellular vesicles derived from human dental pulp stem cells promote osteogenesis of adipose-derived stem cells via the MAPK pathway.

doi: 10.1177/2041731420975569

Figure Lengend Snippet: Figure 1. HDPSCs improved the osteogenic differentiation of hADSCs, probably via EVs. HDPSCs and hADSCs were co-cultured in the presence of GW4869 or DMSO. (a) ALP staining of the co-cultured hDPSCs and hADSCs. (b) Quantitative analysis of ALP activity in the co-cultured hDPSCs and hADSCs. (c) Alizarin Red S staining of the co-cultured hDPSCs and hADSCs. Calcium nodules are indicated by white arrows. (d, e) PCR detection of BMP2 and RUNX2 expression involved in osteogenic differentiation of co-cultured hDPSCs and hADSCs. Data are presented as the mean ± standard deviation of the mean (n = 3), * represents p < 0.05, ** represents p < 0.01.

Article Snippet: HADSCs were fixed were sequentially incubated with primary antibodies against RUNX2 (1:1600, Cell Signaling Technology) and OCN (1:1600, Cell Signaling Technology) overnight at 4°C.

Techniques: Cell Culture, Staining, Activity Assay, Expressing, Standard Deviation

Journal: Journal of tissue engineering

Article Title: Extracellular vesicles derived from human dental pulp stem cells promote osteogenesis of adipose-derived stem cells via the MAPK pathway.

doi: 10.1177/2041731420975569

Figure Lengend Snippet: Figure 3. The effects of hDPSC-EVs on the migration and osteogenic differentiation of hADSCs. (a) Transwell migration assay to detect the effect of hDPSC-EVs on the migration of hADSCs. (b) Quantitative analysis of the effects of hDPSC-EVs on the migration of hADSCs. (c) ALP staining to detect the effect of hDPSC-EVs on osteogenic differentiation of hADSCs. (d) Quantitative detection of ALP activity to detect the effects of hDPSC-EVs on osteogenic differentiation of hADSCs. (e, f) The effects of hDPSC- EVs on the expression of the osteogenic-related genes RUNX2 and BMP2 in hADSCs. (g, h) Immunofluorescence detection of RUNX2 and OCN expression in hADSCs after 7 days incubation with 40 µg/mL hDPSC-EVs. Data are presented as the mean ± standard deviation of the mean (n = 3), * represents p < 0.05, ** represents p < 0.01.

Article Snippet: HADSCs were fixed were sequentially incubated with primary antibodies against RUNX2 (1:1600, Cell Signaling Technology) and OCN (1:1600, Cell Signaling Technology) overnight at 4°C.

Techniques: Migration, Transwell Migration Assay, Staining, Activity Assay, Expressing, Immunofluorescence, Incubation, Standard Deviation

Journal: Materials (Basel, Switzerland)

Article Title: The Effects of Tricalcium-Silicate-Nanoparticle-Containing Cement: In Vitro and In Vivo Studies.

doi: 10.3390/ma16124451

Figure Lengend Snippet: Figure 11. Immunohistochemical staining of Runx2. Light micrographs of sagittal sections of the PDL at root areas of the control (A,D,G), the MTA (B,E,H) and the Biodentine (C,F,I) groups at day 7 (A–C), at day 14 (D–F) and at day 28 (G–I). (J) Graph showing the number of Runx2-positive cells in the PDL at root areas from the control, MTA and Biodentine groups at days 7, 14 and 28. (* p < 0.05) Arrows; Runx2-positive cells. Scale bars: 50 µm (Arrows; Runx2-positive cells. Scale bars: 50 µm).

Article Snippet: The primary antibody used was Runx2 (sc-390351, 1:50; Santa Cruz Biotechnology, Dal- Materials 2023, 16, 4451 6 of 20 las, TX, USA).

Techniques: Immunohistochemical staining, Staining, Control

Journal: IEEE Open Journal of Nanotechnology

Article Title: Osteogenic Effect of Rabbit Periosteum-Derived Precursor Cells Co-Induced by Electric Stimulation and Adipose-Derived Stem Cells in a 3D Co-Culture System

doi: 10.1109/ojnano.2021.3131653

Figure Lengend Snippet: FIGURE 7. Double immunofluorescence staining showing protein expressions of the PDPCs after receiving ES treatment and co-culturing with ADSCs for 2 days. The ES treatment conditions were 0.7 v/cm, 80 kHz, and 3 h/day. The cell nuclei was stained by DPAI fluorescence (blue). The RUNX2 protein was stained by FITC fluorescence (green). The OPN protein was stained by iFlour 594 fluorescence (red).

Article Snippet: After washing, the cell-hydrogel construct was incubated with primary antibodies including diluted FITC-conjugated rabbit anti-RUNX2 polyclonal antibody (ARP36679; AVIVA SYSTEMS BIOSYSTEM, USA) and mouse anti-OPN monoclonal antibody (MBS555003; MyBioSource, USA) in PBS for 2 h at room temperature or overnight at 4 °C avoiding from the light.

Techniques: Staining

Journal: British Journal of Cancer

Article Title: Breast osteoblast-like cells: a new biomarker for the management of breast cancer

doi: 10.1038/s41416-018-0255-y

Figure Lengend Snippet: Breast osteoblast-like cells (BOLCs) and the expression of breast cancer biomarkers. a Graph shows the Nottingham histological score of breast-infiltrating carcinomas. b Graph displays the number of BOLCs in G1, G2 and G3 groups (Nottingham score). c Image shows BOLCs in infiltrating breast cancer; RANKL expression Texas-Red, RUNX2 expression FITC (scale bar represents 20 µm). d High magnification of BOLCs; RANKL expression Texas-Red, RUNX2 expression FITC (scale bar represents 50 µm). e Graph displays the correlation between BOLCs and the number of TGFβ-positive cells ( p < 0.0001; R 2 0.865). Representative image of TGFβ cancer-positive cells in a breast-infiltrating carcinoma (scale bar represents 100 µm). f Graph shows the correlation between BOLCs and the number of vimentin-positive cells ( p < 0.0001; R 2 0.810). Representative image of vimentin cancer-positive cells in a breast-infiltrating carcinoma (scale bar represents 80 µm). g Graph displays the correlation between BOLCs and the percentage of Ki67-positive cells ( p < 0.0001, R 2 0.859). Representative image of Ki67 cancer-positive cells in a breast-infiltrating carcinoma (scale bar represents 100 µm). h Graph shows the correlation between BOLCs and the number of CD44-positive cells ( p < 0.0001, R 2 0.627). Representative image of CD44 cancer-positive cells in a breast-infiltrating carcinoma (scale bar represents 100 µm). i Graph displays the correlation between BOLCs and the number of ER-positive cells ( p < 0.0001, R 2 0.827). Representative image of ER cancer-positive cells in a breast-infiltrating carcinoma (scale bar represents 100 µm). j Graph shows the number of BOLCs in score 0, score 1, score 2 and score 3 groups (Her2 scoring system) ( p = 0.581). Representative image of HER2 cancer-positive cells in a breast-infiltrating carcinoma (scale bar represents 100 µm)

Article Snippet: Sections were then incubated for 1 h at room temperature with the following primary antibodies diluted 1:100: RUNX2 (clone 1D8, Novus Biologicals, USA), RANKL (clone 12A668, Abcam, Cambridge, UK) vimentin (clone 2D1, Novus Biologicals), TGFβ (clone 1D11.16.8, Ki67, Novus Biologicals), CD44 (clone 8E2F3, Novus Biologicals), ER (clone SP1, Novus Biologicals), and HER2 (clone 4B5, Ventana, Tucson, USA).

Techniques: Expressing

Journal: Molecular Medicine Reports

Article Title: LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2

doi: 10.3892/mmr.2019.10191

Figure Lengend Snippet: Plasma RUNX2 mRNA levels are upregulated in colorectal adenocarcinoma patients and are positively correlated with the levels of lncRNA LINC01638. (A) Plasma RUNX2 mRNA levels were upregulated in colorectal adenocarcinoma patients compared to healthy controls (*P<0.05). Plasma levels of RUNX2 mRNA and lncRNA LINC01638 were positively correlated in (B) colorectal adenocarcinoma patients but not in (C) healthy controls.

Article Snippet: Antibodies used in this study included primary antibodies of rabbit anti-human RUNX2 (1:1,500; cat. no. ab23981; Abcam, Shanghai, China) and (1:1,500; cat. no. ab9485; Abcam) and secondary antibody goat anti-rabbit IgG-HRP (1:1,200; cat. no. MBS435036; MyBioSource, San Diego, CA, USA).

Techniques: Clinical Proteomics

Journal: Molecular Medicine Reports

Article Title: LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2

doi: 10.3892/mmr.2019.10191

Figure Lengend Snippet: LINC01638 shRNA silencing mediates downreguatin of RUNX2 in cells of WiDr and HT-29 human colorectal adenocarcinoma cell lines. (A) LINC01638 shRNA silencing led to significantly downregulated expression of RUNX2 protein in cells of WiDr and HT-29 human colorectal adenocarcinoma cell lines, while (B) RUNX2 overexpression failed to significanly affect the expression of LINC01638 (*P<0.05).

Article Snippet: Antibodies used in this study included primary antibodies of rabbit anti-human RUNX2 (1:1,500; cat. no. ab23981; Abcam, Shanghai, China) and (1:1,500; cat. no. ab9485; Abcam) and secondary antibody goat anti-rabbit IgG-HRP (1:1,200; cat. no. MBS435036; MyBioSource, San Diego, CA, USA).

Techniques: shRNA, Expressing, Over Expression

Journal: Molecular Medicine Reports

Article Title: LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2

doi: 10.3892/mmr.2019.10191

Figure Lengend Snippet: LINC01638 shRNA inhibits cancer cell proliferation possibly through RUNX2. LINC01638 shRNA silencing (shRNA) significantly inhibited, while RUNX2 overexpression (RUNX2) significantly promoted the proliferation of cells of both (A) WiDr and (B) HT-29 human colorectal adenocarcinoma cell lines. In addition, RUNX2 overexpression partially reversed the advese effect of LINC01638 shRNA silencing on cancer cell proliferation (*P<0.05).

Article Snippet: Antibodies used in this study included primary antibodies of rabbit anti-human RUNX2 (1:1,500; cat. no. ab23981; Abcam, Shanghai, China) and (1:1,500; cat. no. ab9485; Abcam) and secondary antibody goat anti-rabbit IgG-HRP (1:1,200; cat. no. MBS435036; MyBioSource, San Diego, CA, USA).

Techniques: shRNA, Over Expression

Journal: FEBS Open Bio

Article Title: In vitro evaluation of periapical lesion‐derived stem cells for dental pulp tissue engineering

doi: 10.1002/2211-5463.13336

Figure Lengend Snippet: Primers used in the qRT‐PCR.

Article Snippet: The membranes were blocked with 5% non‐fat milk and incubated with primary antibodies against RUNX family transcription factor 2 (RUNX2) (dilution 1 : 500; #12556S; Cell Signaling Technology, Danvers, MA, USA), dentin sialophosphoprotein (DSPP) (dilution 1 : 500; sc‐73632, Santa Cruz Biotechnology, Santa Cruz, CA, USA), dentin matrix protein 1 (DMP1) (dilution 1 : 500; ab103203; Abcam, Cambridge, UK), Sp7 transcription factor (SP7) (dilution 1 : 1000; PA5‐115697; Thermo Fisher), VEGF (dilution 1 : 100; MA5‐13182; Thermo Fisher), GDNF (dilution 1 : 200; 711074; Thermo Fisher) and GAPDH (WB0197; Biotechwell) and were then incubated with HRP‐conjugated secondary antibodies (dilution 1 : 5000; Biotechwell).

Techniques: Sequencing

Journal: FEBS Open Bio

Article Title: In vitro evaluation of periapical lesion‐derived stem cells for dental pulp tissue engineering

doi: 10.1002/2211-5463.13336

Figure Lengend Snippet: Comparison of the osteo/odontogenic capacities of the cells. (A) ALP staining after osteo/odontogenic induction for 3 and 7 days. Scale bar = 500 μm. (B) Alizarin red staining showing the presence of calcified nodules after 7, 14, 21 and 28 days of osteo/odontogenic induction. Scale bar = 500 μm. (C) Gene expression patterns of ALP , RUNX2 and DSPP after osteogenic induction for 3 and 7 days; the expression level was normalized to that of ACTB ( n = 3, Student’s t ‐test). * P < 0.05, ** P < 0.01. (D) Western blotting detection (upper) and imagej analysis (below) of DSPP, DMP1, RUNX2 and SP7 after osteogenic induction for 7, 14 and 21 days. Data are shown as the mean ± SD.

Article Snippet: The membranes were blocked with 5% non‐fat milk and incubated with primary antibodies against RUNX family transcription factor 2 (RUNX2) (dilution 1 : 500; #12556S; Cell Signaling Technology, Danvers, MA, USA), dentin sialophosphoprotein (DSPP) (dilution 1 : 500; sc‐73632, Santa Cruz Biotechnology, Santa Cruz, CA, USA), dentin matrix protein 1 (DMP1) (dilution 1 : 500; ab103203; Abcam, Cambridge, UK), Sp7 transcription factor (SP7) (dilution 1 : 1000; PA5‐115697; Thermo Fisher), VEGF (dilution 1 : 100; MA5‐13182; Thermo Fisher), GDNF (dilution 1 : 200; 711074; Thermo Fisher) and GAPDH (WB0197; Biotechwell) and were then incubated with HRP‐conjugated secondary antibodies (dilution 1 : 5000; Biotechwell).

Techniques: Comparison, Staining, Gene Expression, Expressing, Western Blot

Journal: Bioengineering

Article Title: An Injectable, Osteoconductive Gelatin-Enabled GelMA/HAp Hydrogel Scaffold for Minimally Invasive Bone Tissue Engineering

doi: 10.3390/bioengineering13020139

Figure Lengend Snippet: ( a ) Immunofluorescence images of Runx2 in BMSCs co-cultured with hydrogels during osteogenic differentiation. ( b ) Number of Runx2-positive cells in BMSCs co-cultured with hydrogels. *** p < 0.005; **** p < 0.0001.

Article Snippet: The fixed samples were permeabilized and blocked, followed by incubation with a primary antibody against Runx2 (Shanghai, China, Proteintech, 20700-1-AP) and then with the corresponding fluorophore-conjugated secondary antibody (USA, Thermo Fisher Scientific, A-11011).

Techniques: Immunofluorescence, Cell Culture

Journal: Bioengineering

Article Title: An Injectable, Osteoconductive Gelatin-Enabled GelMA/HAp Hydrogel Scaffold for Minimally Invasive Bone Tissue Engineering

doi: 10.3390/bioengineering13020139

Figure Lengend Snippet: ( a – d ) qPCR analysis of OCN , COL-1 , Runx2 and Osterix in BMSCs on Day 7 and 14. * p < 0.05; **** p < 0.0001.

Article Snippet: The fixed samples were permeabilized and blocked, followed by incubation with a primary antibody against Runx2 (Shanghai, China, Proteintech, 20700-1-AP) and then with the corresponding fluorophore-conjugated secondary antibody (USA, Thermo Fisher Scientific, A-11011).

Techniques: